Penn Vaccine Trial for Early Breast Cancer Proves 'Promising'

February 2, 2012

United Press International

The United Press International covered the results of two new studies examining a personalized vaccine for the early breast cancer ductal carcinoma in situ led by Brian Czerniecki, MD, PhD, surgical director of the Rena Rowan Breast Center and Surgical Director of the Immunotherapy Program for the Abramson Cancer Center. The results show that vaccination with an anti-HER2 dendritic cell vaccine made partly from the patient’s own cells triggers a complete tumor eradication in nearly 20 percent of women with the disease. And more than 85 percent of patients treated appear to have a sustained immune response after vaccination... Read More

Related Information

Additional Coverage